Abstract
This article highlights a unique time in the history of hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure hepatitis C is discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Cyclophilins / antagonists & inhibitors*
-
Cyclosporine / therapeutic use
-
Cyclosporins / therapeutic use
-
Drug Therapy, Combination
-
Enzyme Inhibitors / therapeutic use*
-
Hepacivirus / enzymology*
-
Hepacivirus / genetics
-
Hepatitis C / drug therapy*
-
Humans
-
Interferon-alpha / therapeutic use
-
Polyethylene Glycols / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
-
Viral Nonstructural Proteins / antagonists & inhibitors
Substances
-
Antiviral Agents
-
Cyclosporins
-
Enzyme Inhibitors
-
Interferon-alpha
-
Recombinant Proteins
-
Viral Nonstructural Proteins
-
Polyethylene Glycols
-
Ribavirin
-
Cyclosporine
-
(melle-4)cyclosporin
-
NS-5 protein, hepatitis C virus
-
Cyclophilins
-
peginterferon alfa-2a
-
alisporivir
-
SCY-635